Eprenetapopt

Eprenetapopt (APR-246) is an experimental anti-cancer drug which acts by reactivating certain mutant forms of p53, a tumour-suppressing gene which is commonly mutated into inactive forms as an early step in the development of malignant cancers. It has been researched over many years for treatment of numerous forms of cancer and reached late-stage clinical trials, but has never yet been approved for medical use due to inconsistent results. Nevertheless, it continues to be studied especially as a combination treatment alongside other anti-cancer medications, or in patients whose cancers have particular mutant forms of p53 thought to be susceptible to treatment with eprenetapopt.^{[1][2][3][4][5]}

CAS Number

• 5291-32-7

PubChem CID

• 52918385

DrugBank

• DB11684

ChemSpider

• 24606048

Quick facts Identifiers, CAS Number ...

Eprenetapopt

Identifiers
IUPAC name 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one
CAS Number	5291-32-7
PubChem CID	52918385
DrugBank	DB11684
ChemSpider	24606048
UNII	Z41TGB4080
KEGG	D12192
ChEMBL	ChEMBL3186011
CompTox Dashboard (EPA)	DTXSID401164013
Chemical and physical data
Formula	C10H17NO3
Molar mass	199.250 g·mol−1
3D model (JSmol)	Interactive image
SMILES COCC1(C(=O)C2CCN1CC2)CO
InChI InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3 Key:BGBNULCRKBVAKL-UHFFFAOYSA-N

Close